All In Biotech

NDA 204708 · Galderma Labs Lp

Mirvaso

Brimonidine Tartrate · Topical

Last checked: Nov 19, 2026Latest source record: Jul 27, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Aug 23, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

177

44 Phase 3, 5 recruiting

FAERS reports

4,408

1,945 serious, 191 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 24, 2024.

MIRVASO (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. MIRVASO (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.( 1 )

Mechanism: Brimonidine is a relatively selective alpha-2 adrenergic agonist. Topical application of MIRVASO topical gel may reduce erythema through direct vasoconstriction.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MIRVASO · BRIMONIDINE TARTRATE EQ 0.33% BASE · GEL, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Brimonidine" as an intervention, any sponsor and status, largest first.

All 177 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • erythema578
  • drug ineffective297
  • eye pain289
  • flushing285
  • condition aggravated276
  • product use issue256
  • eye irritation227
  • headache196
  • fatigue194
  • skin burning sensation179
  • rosacea174
  • vision blurred173

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200428
200539
200636
200753
200837
200945
201055
201181
201277
2013101
2014334
2015346
2016234
2017219
2018200
2019196
2020301
2021242
2022259
2023301
2024333
2025381
2026510

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mirvaso (Brimonidine Tartrate)

2024 spending

$395K

Beneficiaries

264

586 claims

Per beneficiary

$1,497

$20.58 per unit

View as table
YearSpending
2020$2,017,667
2021$2,070,539
2022$2,219,876
2023$898,665
2024$395,172

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 312 on PubMed

Sponsor: Galderma Labs Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.